Search Results
Jan 07, 2026, 09:00 ET Helix Announces Multi-Year Strategic Collaboration with GSK to Drive Precision Medicine Development
GSK, the global biopharma company. This agreement provides GSK access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas.
More news about: Helix
Jan 07, 2026, 08:50 ET Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
clinical development, medical affairs, new product strategy, and in-line commercialization including global launch teams at top companies including Merck, GSK, Akcea, and Ionis. Her record includes leading commercial activities in the U.S., globally and in international markets. In her roles she has shaped
More news about: Aspen Neuroscience, Inc.
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Exdensur (depemokimab) developed by GSK | AsthmaA monoclonal antibody targeting IL-5, administered subcutaneously twice yearly to treat asthma in adolescents and adults, also under
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Exdensur (depemokimab) developed by GSK | AsthmaA monoclonal antibody targeting IL-5, administered subcutaneously twice yearly to treat asthma in adolescents and adults, also under
More news about: Clarivate Plc
Dec 21, 2025, 17:43 ET Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint
More news about: Samsung Biologics
Dec 17, 2025, 10:20 ET Disease-Modifying Therapies Market to Surpass USD 112.6 Billion by 2033 as Biologic Innovation Redefines Long-Term Disease Control
generating over USD 55 billion in annual revenue, a significant portion driven by disease-modifying therapies.AstraZeneca and GSK are expanding immune-modulation pipelines, integrating biologics and precision medicine strategies.Amgen Inc. and UCB, Inc. continue
More news about: DataM Intelligence 4 Market Research LLP
Dec 15, 2025, 09:01 ET New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use
of quillay saponins for all approved and late-phase vaccines using them as adjuvants. Approved vaccines that contain QS-21 are made by two companies: GSK and Novavax. Additional suppliers of quillay saponins are positioned to claim some market share in the coming years, but even then, the quillay market
More news about: Treatment Action Group
Dec 12, 2025, 20:25 ET U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GlaxoSmithKline [GSK] in 2019) for exclusive rights to niraparib in prostate cancer.For more information visit
More news about: Johnson & Johnson
Dec 12, 2025, 09:00 ET CData Recognized for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools
unlock the full value of their data.""With CData, everything just works automatically," said Michael Hinkle, Medical Engagement Systems Architect, GSK. "When something changes in Oracle, there's no coding and no waiting on IT. That simplicity has freed us to think bigger about data integration by connecting
More news about: CData Software
Dec 10, 2025, 17:31 ET Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
Panbela Therapeutics, Taiho Pharmaceutical, Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx,
More news about: DelveInsight Business Research, LLP
Dec 09, 2025, 10:20 ET Immunostimulant Market to Reach $288.82 billion, Globally, by 2034 at 9.9% CAGR: Allied Market Research
Institute of India Pvt. Ltd.Novartis AGF. Hoffmann-La Roche Ltd.Johnson & JohnsonEmergent BioSolutions Inc.GSKExplore AMR's Extensive Ongoing Coverage on Life Science Industry:
More news about: Allied Market Research
Dec 09, 2025, 05:57 ET American Lung Association Launches Campaign to Help New England Residents Stay Healthy This Winter
Lung.org/vaccines.Support for this campaign is provided by GSK.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving
More news about: American Lung Association
Dec 08, 2025, 12:00 ET AXA XL Joins ISASecure to Strengthen Cybersecurity Risk Prevention Through the Adoption of ISA/IEC 62443 Cybersecurity Standards
practices meet internationally recognized benchmarks for OT security.ISASecure's global ecosystem includes leaders such as Chevron, ExxonMobil, GSK, Saudi Aramco, Honeywell, Johnson Controls, National Cyber Security Agency – Qatar, Schneider Electric, Siemens, Trane Technologies and Yokogawa, among
More news about: The International Society of Automation
Dec 08, 2025, 08:00 ET Ouro Medicines Receives U.S. FDA Orphan Drug Designation for Gamgertamig (OM336) for Immune Thrombocytopenia
remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA and Norwest. For more information visit
More news about: Ouro Medicines
Dec 03, 2025, 10:43 ET HIV Therapeutics Market to Reach USD 57.56 Billion by 2033 as Long-Acting Regimens, Integrase Inhibitors, and Next-Gen Combination Therapies Redefine Global HIV Care
Focus)Significant R&D invested by parent company GSK in LAI and next-gen INSTI pipeline.Focused
More news about: DataM Intelligence 4 Market Research LLP
Dec 01, 2025, 10:01 ET Respiratory Syncytial Virus Market to Reach USD 4.54 Billion by 2033 as Global Uptake of Next-Generation Vaccines & Monoclonal Antibodies Accelerates
billionVaccine Segment: USD 6.7 billionRSV vaccine Abrysvo is expanding into adult and maternal immunization markets.GSK plc2023 Revenue: USD 38.6 billionVaccines Division: USD 11.4 billionArexvy
More news about: DataM Intelligence 4 Market Research LLP
Nov 26, 2025, 10:20 ET Gummy Supplements Market to Reach USD 66.79 Billion by 2031 as Consumer Shift Toward Chewable Wellness Fuels Explosive Growth | According to DataM Intelligence
billionIncludes One A Day®, Flintstones Gummies®, and nutritional gummies across multiple age groups.Haleon Group (Formerly GSK Consumer Health)2024 Revenue: USD 13.2 billionVitamins, Minerals & Supplements (VMS): USD
More news about: DataM Intelligence 4 Market Research LLP
Nov 26, 2025, 06:10 ET Oral Care Market Poised to Grow to USD 86.8 Billion by 2035 with a Thriving CAGR of 6.75% | Vantage Market Research
adoption in value-driven markets.Top Key Players for Oral Care Market Colgate-Palmolive CompanyGSK plcJohnson & Johnson Services, IncChurch & Dwight Co., Inc.Procter & GambleUnilever PLCGC
More news about: Vantage Market Research
Nov 20, 2025, 06:30 ET Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK
(MASH). Under the terms of the agreements, if GSK elects to progress into a further collaboration, ProFound and Quotient will advance their respective programs through key preclinical activities, after which GSK will have the exclusive option to advance the programs into clinical
More news about: Flagship Pioneering
Nov 18, 2025, 04:11 ET Primary Biliary Cholangitis (PBC) Treatment Market to Reach USD 2.72 Billion by 2033, Driven by Next-Generation FXR Agonists & Immunomodulators | DataM Intelligence
Inc. | AbbVie Inc. | Aden Healthcare | Zydus Therapeutics Inc. | COUR Pharmaceuticals | Kowa Company, Ltd. | Mirum Pharma | Parvus Therapeutics Inc. | GSK plc | Strides Pharma Science Limited | Calliditas Therapeutics AB Key Highlights:
More news about: DataM Intelligence 4 Market Research LLP
Nov 18, 2025, 04:03 ET OCHRE BIO COMPLETES HUMAN LIVER FUNCTIONAL GENOMICS AND SINGLE-CELL DATASETS IN PARTNERSHIP WITH GSK
human disease biology. These foundational datasets developed with GSK feed our algorithms (AI) to do just that." Kaivan Khavandi, SVP, Head of Respiratory, Immunology & Inflammation at GSK said: "Our collaboration with Ochre has generated data that supports
More news about: Ochre Bio
Nov 12, 2025, 17:31 ET WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight
2025 for IDE275 (GSK959), including an oral session in the New Drugs on the Horizon series and three poster sessions. The compound has shown selective preclinical efficacy in MSI-H solid tumors and is progressing through a Phase I dose-escalation study in collaboration with GSK.
More news about: DelveInsight Business Research, LLP
Nov 12, 2025, 10:09 ET IDBS announces i3 2026-An exclusive customer and partner event on data management innovation in BioPharma
IDBS Unsung Hero / MVP: Boehringer Ingelheim Design Partnership Champion: GSK Best Use Case of Data Out: KBI Biopharma (sponsored by Zifo)
More news about: IDBS
Nov 11, 2025, 17:31 ET Antibody-Mediated Rejection Market Set to Expand Significantly During the Forecast Period (2025-2034) Amid Advances in Diagnostics and Targeted Therapies | DelveInsight
BioPharma, ViGenCell, Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen, among others. About DelveInsight DelveInsight
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals, among others. About DelveInsight
More news about: DelveInsight Business Research, LLP